Brief: FDA Approves Bomyntra & Conexxence, Biosimilars To Xgeva & Prolia
March 25 (Reuters) - FDA: FDA APPROVES BOMYNTRA & CONEXXENCE, BIOSIMILARS TO XGEVA & PROLIA - WEBSITE Further company coverage: FREG.DE ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresenius SE & Co. KGaA
See all newsFresenius lifts 2026 expectations after strong Q3 (updated)
Healthcare firm Fresenius Q3 revenue rises on Kabi growth; lifts outlook
Brief: Fresenius Sees FY26 EBIT Margin Above 11.5%
Brief: Fresenius SE Q3 Revenue EUR 5,803 Million
Fresenius signs biosimilars pipeline agreement with WuXi Biologics (updated)